Kelly E. McCann, MD, PhD

Kelly E. McCann, MD, PhD, is an assistant professor and breast medical oncologist at UCLA.

Articles

Dr McCann on the Increasing Use of TKIs for HER2+ Breast Cancer Brain Metastases

April 7th 2025

Kelly E. McCann, MD, PhD, discusses the benefit of using TKI combinations for patients with HER2-positive breast cancer and brain metastases.

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

March 31st 2025

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Dr McCann on the Ongoing Development of Tailored Treatment Regimens in HER2+ Breast Cancer

March 12th 2025

Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

February 13th 2025

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

August 6th 2024

A panel of experts offer future perspectives in HR+ breast cancer.

Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

August 6th 2024

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

July 29th 2024

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

July 29th 2024

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

July 29th 2024

A panel of experts discuss navigating 2L treatment strategies.

Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

July 29th 2024

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

July 8th 2024

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

July 8th 2024

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

June 25th 2024

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

June 25th 2024

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.